MARKET

CORT

CORT

Corcept
NASDAQ

Real-time Quotes | Nasdaq Last Sale

13.30
+0.20
+1.53%
After Hours: 13.30 0 0.00% 16:07 12/06 EST
OPEN
13.13
PREV CLOSE
13.10
HIGH
13.48
LOW
13.13
VOLUME
1.17M
TURNOVER
--
52 WEEK HIGH
19.48
52 WEEK LOW
9.14
MARKET CAP
1.52B
P/E (TTM)
18.86
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of CORT and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

CORT News

  • Why Is Corcept (CORT) Down 8.9% Since Last Earnings Report?
  • Zacks.1d ago
  • Why Corcept Therapeutics Incorporated's (NASDAQ:CORT) High P/E Ratio Isn't Necessarily A Bad Thing
  • Simply Wall St..4d ago
  • Corcept Therapeutics Shares Halted On Circuit Breaker, Down 15.6% For Session
  • Benzinga.11/20 20:18
  • Corcept Therapeutics Shares Fall As Hearing Teva Patent Trial Against Co.'s '214 Korlym Has Been Instituted By Patent Trial, Appeal Board As Patent Claims Determined to Be Likely Invalid
  • Benzinga.11/20 20:16

More

Industry

Pharmaceuticals
+0.45%
Pharmaceuticals & Medical Research
+0.49%

Hot Stocks

Name
Price
%Change

About CORT

Corcept Therapeutics Incorporated is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The Company is developing mifepristone, a compound that modulates the effects of cortisol by acting as a competitive antagonist at the glucocorticoid receptor (GR). As of December 31, 2016, it had discovered three structurally distinct series of selective cortisol modulators, all of which share mifepristone's affinity for GR but, unlike mifepristone, do not bind to the progesterone receptor. It is conducting two clinical trials of its selective cortisol modulator, CORT125134. One trial is investigating CORT125134 as a treatment for patients with Cushing syndrome. The second trial is investigating the combination of CORT125134 and nab-paclitaxel (Celgene Corporation's Abraxane) to treat patients with solid-tumor cancers.
More

Webull offers Corcept Therapeutics Incorporated (CORT) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.